Boryung Corporation

KOSE:A003850 Stock Report

Market Cap: ₩740.4b

Boryung Dividend

Dividend criteria checks 2/6

Boryung is a dividend paying company with a current yield of 0.89% that is well covered by earnings.

Key information

0.9%

Dividend yield

16%

Payout ratio

Industry average yield1.1%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share₩605.40
Dividend yield forecast in 3Y0.9%

Recent dividend updates

Recent updates

Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

Apr 06
Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price

A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Apr 28
A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)

Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Mar 17
Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet

Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Feb 27
Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend

Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 09
Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Jan 25
Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?

Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

Jan 10
Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?

If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Dec 23
If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns

Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Dec 08
Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?

Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Nov 23
Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, A003850 has been paying a dividend for less than 10 years.

Growing Dividend: A003850's dividend payments have increased, but the company has only paid a dividend for 5 years.


Dividend Yield vs Market

Boryung Dividend Yield vs Market
How does A003850 dividend yield compare to the market?
SegmentDividend Yield
Company (A003850)0.9%
Market Bottom 25% (KR)1.0%
Market Top 25% (KR)3.5%
Industry Average (Pharmaceuticals)1.1%
Analyst forecast in 3 Years (A003850)0.9%

Notable Dividend: A003850's dividend (0.89%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (1%).

High Dividend: A003850's dividend (0.89%) is low compared to the top 25% of dividend payers in the KR market (3.53%).


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (16.4%), A003850's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (34.6%), A003850's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.